U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients

BACKGROUND: Patients with chronic hepatitis C genotype 1 (HCV-1) and difficult-to-treat characteristics respond poorly to pegylated interferon alfa and ribavirin (RBV), and could benefit from an interferon with increased activity (consensus interferon or CIFN), favorable viral kinetics from daily do...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Samuel B., Aqel, Bashar, Dieperink, Eric, Liu, Shanglei, Tetrick, Lori, Falck-Ytter, Yngve, DeComarmond, Charles, Smith, Coleman I., McKee, Daniel P., Boyd, William, Kulig, Clark C., Bini, Edmund J., Pedrosa, Marcos C.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041922/
https://www.ncbi.nlm.nih.gov/pubmed/21221804
http://dx.doi.org/10.1007/s10620-010-1504-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041922/
https://www.ncbi.nlm.nih.gov/pubmed/21221804
http://dx.doi.org/10.1007/s10620-010-1504-y

Ejemplares similares